JP Morgan

Doosan Bobcat’s planned W2.4tr ($2.2bn) IPO in South Korea fell through this week on the back of an over-aggressive pricing strategy. Investors also withdrew their support after poor communication from the leads apparently resulted in conflicting messages on the progress of the bookbuilding. John Loh reports.

Cabot Credit Management, the debt purchasing and recovery business, has amended its senior secured revolving credit facility and lowered the margin but kept the same group of lenders.

Haitong International Securities Group has printed its first convertible bond in two years. It is the first zero coupon CB from an international arm of a Chinese securities house, said bankers close to the deal.

KEB Hana Bank executed a $650m dual-tranche offering on Tuesday, ahead of an expected burst of supply from financial names. While the issuer priced the longer five year portion flat to its outstanding curve, it decided to be slightly generous with the three year to bag a larger amount.

Rentenbank tapped its new 10 year Kangaroo line for A$50m ($37.8m) on Tuesday. Attracting a mixture of Asian accounts, the agency's long dated paper pulled in a wide range of investors.

Maturing deals issued by Washington Mutual and National Bank of Greece show covered bonds doing precisely what they're supposed to — redeem in full and on time.

PureGym, the UK’s largest gym operator, has pulled the plug on its £219m London IPO after finding weak demand, in another blow to the autumn equity capital markets pipeline.

Investment grade corporate issuers hit the euro bond markets in force on Tuesday with five primary transactions in play, but defensive deal sizes characterised the frantic flow.

Some eight banks that arranged Saudi Arabia’s $10bn loan in May have secured berths on the sovereign's bond extravaganza that is due to kick off this week.

Fullerton Healthcare Corp has wrapped up its Singapore listing at the bottom of guidance, valuing the deal at S$213.3m ($154.7m).

South Korea’s KEB Hana Bank has received positive feedback from investors for its dual-tranche 144A/Reg S trade, launched on Tuesday morning.

China Resources Pharmaceutical Group will raise as much as HK$15.6bn ($2.0bn) via a Hong Kong IPO after firming up the price range.